ATE179458T1 - Verwendung von papillomavirusprotein l2 zur therapeutischen behandlung von durch papillomavirus hervorgerufenen tumoren oder oder anderen krankhaften veränderungen - Google Patents

Verwendung von papillomavirusprotein l2 zur therapeutischen behandlung von durch papillomavirus hervorgerufenen tumoren oder oder anderen krankhaften veränderungen

Info

Publication number
ATE179458T1
ATE179458T1 AT92912857T AT92912857T ATE179458T1 AT E179458 T1 ATE179458 T1 AT E179458T1 AT 92912857 T AT92912857 T AT 92912857T AT 92912857 T AT92912857 T AT 92912857T AT E179458 T1 ATE179458 T1 AT E179458T1
Authority
AT
Austria
Prior art keywords
papilloma virus
tumors
therapeutic treatment
protein
changes caused
Prior art date
Application number
AT92912857T
Other languages
English (en)
Inventor
William Fleming Hoggan Jarrett
Maria Saveria Campo
Kenneth Thomas Smith
Original Assignee
Cancer Res Campaign Tech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Res Campaign Tech filed Critical Cancer Res Campaign Tech
Application granted granted Critical
Publication of ATE179458T1 publication Critical patent/ATE179458T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Transceivers (AREA)
  • Mobile Radio Communication Systems (AREA)
AT92912857T 1991-06-26 1992-06-17 Verwendung von papillomavirusprotein l2 zur therapeutischen behandlung von durch papillomavirus hervorgerufenen tumoren oder oder anderen krankhaften veränderungen ATE179458T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9113809A GB9113809D0 (en) 1991-06-26 1991-06-26 Papillomavirus l2 protein

Publications (1)

Publication Number Publication Date
ATE179458T1 true ATE179458T1 (de) 1999-05-15

Family

ID=10697369

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92912857T ATE179458T1 (de) 1991-06-26 1992-06-17 Verwendung von papillomavirusprotein l2 zur therapeutischen behandlung von durch papillomavirus hervorgerufenen tumoren oder oder anderen krankhaften veränderungen

Country Status (11)

Country Link
US (2) US6380157B1 (de)
EP (1) EP0592480B1 (de)
JP (1) JP3533216B2 (de)
AT (1) ATE179458T1 (de)
AU (1) AU662910B2 (de)
DE (1) DE69229050T2 (de)
DK (1) DK0592480T3 (de)
ES (1) ES2133322T3 (de)
GB (1) GB9113809D0 (de)
GR (1) GR3030716T3 (de)
WO (1) WO1993000436A1 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9207701D0 (en) * 1992-04-08 1992-05-27 Cancer Res Campaign Tech Papillomavirus e7 protein
US5618536A (en) * 1992-09-03 1997-04-08 The United States Of America As Represented By The Department Of Health And Human Services Chimeric papillomavirus-like particles
US20020164350A1 (en) 1992-09-03 2002-11-07 Lowy Douglas R. Chimeric papillomavirus-like particles
GB9306731D0 (en) * 1993-03-31 1993-05-26 Cancer Res Campaign Tech Vaccines
AU719837B2 (en) * 1993-03-31 2000-05-18 Cancer Research Campaign Technology Limited Pharmaceuticals based on papillomaviruses
AUPM358894A0 (en) * 1994-01-31 1994-02-24 Csl Limited Modified papilloma virus l2 protein and vlps formed therefrom
AU717932B2 (en) * 1994-10-06 2000-04-06 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Chimeric papillomavirus-like particles
AU717647B2 (en) * 1994-10-06 2000-03-30 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Chimeric papillomavirus-like particles
GB9420146D0 (en) * 1994-10-06 1994-11-23 Cancer Res Campaign Tech Papillomavirus vaccine
DE122007000092I1 (de) 1994-10-07 2008-03-27 Univ Loyola Chicago Papillomavirusähnliche partikel, fusionsproteine sowie verfahren zu deren herstellung
JP3958360B2 (ja) * 1995-02-24 2007-08-15 キャンタブ ファーマシューティカルズ リサーチ リミティド 免疫治療剤として役立つポリペプチド及びポリペプチド調製の方法
GB9505784D0 (en) * 1995-03-22 1995-05-10 Lynxvale Ltd Anti-tumour treatment
US7118754B1 (en) 1996-07-30 2006-10-10 Transgene S.A. Pharmaceutical composition for treating papillomavirus tumors and infection
AU781653B2 (en) * 1996-07-30 2005-06-02 Transgene S.A. Pharmaceutical composition for treating papollomavirus tumour and infection
FR2751879B1 (fr) * 1996-07-30 1998-10-30 Transgene Sa Composition pharmaceutique contre les tumeurs et infections a papillomavirus
GB9621091D0 (en) 1996-10-09 1996-11-27 Fondation Pour Le Perfectionem Attenuated microorganisms strains and their uses
FR2766091A1 (fr) * 1997-07-18 1999-01-22 Transgene Sa Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee
CA2229955C (en) 1998-02-20 2003-12-09 Medigene Gmbh Papilloma virus capsomere vaccine formulations and methods of use
US20020039584A1 (en) 1998-02-20 2002-04-04 Medigene Ag Papilloma virus capsomere vaccine formulations and methods of use
US7182947B2 (en) 1998-02-20 2007-02-27 Medigene Ag Papillomavirus truncated L1 protein and fusion protein constructs
US7494658B2 (en) 1998-02-20 2009-02-24 Medigene Ag Papilloma virus truncated L1 protein and fusion protein constructs
US6926897B1 (en) 1998-03-24 2005-08-09 Medigene Aktiengesellschaft Medicament for the avoidance or treatment of papillomavirus-specific tumour
DE19905883C2 (de) * 1999-02-11 2001-05-23 Deutsches Krebsforsch Chimäre Virus-ähnliche Partikel bzw. chimäre Capsomere von BPV
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
NZ523408A (en) * 2000-06-26 2006-02-24 Stressgen Biotechnologies Corp Human papilloma virus treatment
WO2002004007A2 (en) * 2000-07-06 2002-01-17 Georgetown University Stable (fixed) forms of viral capsid proteins, fusion proteins and uses thereof
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
US20080160040A1 (en) * 2004-04-15 2008-07-03 Ghim Shin-Je Plant-produced compositions for treating papillomavirus infection and related methods
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
DE102008010954A1 (de) 2008-02-25 2009-08-27 Cichon, Günter, Prof.Dr. DNA-Vakzine zur Therapie und Prophylaxe von Gebärmutterhalskrebs und seinen prämalignen Vorstufen
US9623098B2 (en) 2008-05-26 2017-04-18 Cadila Healthcare Limited Combined measles-human papilloma vaccine
ES2641892T3 (es) * 2009-08-26 2017-11-14 Selecta Biosciences, Inc. Composiciones que inducen la ayuda de las células T
US9717783B2 (en) 2010-02-09 2017-08-01 Stc.Unm Immunogenic HPV L2-containing VLPs and related compositions, constructs, and therapeutic methods
US9533057B2 (en) 2010-02-09 2017-01-03 Stc.Unm Immunogenic HPV L2-containing VLPs and related compositions, constructs, and therapeutic methods
CN104159606A (zh) * 2012-01-12 2014-11-19 Stc.Unm公司 含有hpv l2的免疫原性vlp及相关组合物和方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0133123A1 (de) * 1983-07-25 1985-02-13 Mgi Pharma, Inc. Papillomavirus-Immunogene
US4777239A (en) 1986-07-10 1988-10-11 The Board Of Trustees Of The Leland Stanford Junior University Diagnostic peptides of human papilloma virus
FR2632956B2 (fr) 1988-05-13 1991-07-12 Pasteur Institut Sondes a papillomavirus hpv49, hpv50, hpv54, hpv55; produits genetiquement et immunologiquement lies a ce papillomavirus hpv49, hpv50, hpv54, hpv55; procede de diagnostic in vitro d'infections a papillomavirus et d'immunisation in vivo contre ces papillomavirus

Also Published As

Publication number Publication date
AU662910B2 (en) 1995-09-21
HK1001309A1 (en) 1998-06-12
GB9113809D0 (en) 1991-08-14
DE69229050D1 (de) 1999-06-02
DK0592480T3 (da) 1999-11-08
US6380157B1 (en) 2002-04-30
US20020136736A1 (en) 2002-09-26
AU1985992A (en) 1993-01-25
JP3533216B2 (ja) 2004-05-31
EP0592480B1 (de) 1999-04-28
DE69229050T2 (de) 1999-10-21
WO1993000436A1 (en) 1993-01-07
JPH06508988A (ja) 1994-10-13
ES2133322T3 (es) 1999-09-16
EP0592480A1 (de) 1994-04-20
GR3030716T3 (en) 1999-11-30

Similar Documents

Publication Publication Date Title
ATE179458T1 (de) Verwendung von papillomavirusprotein l2 zur therapeutischen behandlung von durch papillomavirus hervorgerufenen tumoren oder oder anderen krankhaften veränderungen
ATE227587T1 (de) Kombinierte verwendung von hyaluronsäure und therapeutischen wirkstoffen zur verbesserung des therapeutischen effekts
ATE267607T1 (de) Verwendung von löslichen oligomerischen cd40 liganden oder monoklonalen antikörpern zur herstellung eines arzneimitells zur vorbeugung oder behandlung von neoplastischen krankheiten
EP0787802A3 (de)
GB8805792D0 (en) Medicaments
ATE319474T1 (de) Behandlung von autoimmunkrankheiten durch orale verabreichung von autoantigenen
ATE204178T1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
DE69631478D1 (de) Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen
ATE101648T1 (de) Expression eines tumorspezifischen antigens eines rekombinanten virusvektors sowie dessen anwendung zur versorgenden oder heilenden behandlung des entsprechenden tumors.
ZA896150B (en) The use of alpha-amino boronic acid derivatives for the prophylaxis and treatment of virus diseases
ATE135208T1 (de) Verwendung von nervonsäure und langkettiger fettsäuren zur behandlung demyelinisierender erkrankungen
ATE81984T1 (de) Verwendung von granulozyt-makrophagen-kolonie erregenden faktor zur herstellung eines medikaments zur behandlung von bakterieller krankheiten.
DE69826023D1 (de) Verwendung von substanzen mit oxytocinwirkung zur herstellung eines arzneimittels zur behandlung affektiver schmerzsyndrome
DE68904462D1 (de) 4-chinolincarbonsaeure-derivate, brauchbar zur behandlung von haut- und muco-epithelial-gewebekrankheiten.
ATE220923T1 (de) Rekombinante adenoviren und deren verwendung in der gentherapie zur behandlung von augenerkrankungen
ATE107168T1 (de) Verwendung von gepiron zur herstellung eines pharmazeutischen präparats zur behandlung atypischer depression.
ATE174798T1 (de) Die herstellung von zusammensetzungen zur behandlung von krankheiten der zellproliferation
ATE217191T1 (de) Verwendung von phanquinon zur behandlung von alzheimer's krankheit
ATE67675T1 (de) Kombination von gammainterferonen und antientzuendungsmitteln oder antipyretischen mitteln zur behandlung von krankheiten.
ATE181668T1 (de) Verwendung von 5-ht4 rezeptorantagonisten zur behandlung von vorhof-fibrillation und zur vorbeugung von schlaganfall
RU93038888A (ru) Салфетка из тканого углеродного материала
DE59409413D1 (de) Verwendung von n,s-diacetylcystein-ethylester (dacee) zur herstellung eines medikaments zur behandlung viraler erkrankungen
DE59302465D1 (de) Verwendung von bärlauch zur therapie oder prophylaxe von durchblutungsstörungen
ATE239492T1 (de) Verwendung von einem bpi protein zur herstellung eines medikamentes zur behandlung von chronischen herzerkrankungen
DE69427116D1 (de) Verwendung von 4'-iodo - 4 - deoxydoxorubicin zur behandlung von amyloidosis

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee